MedTrace Logo

Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects

NCT03534648 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-09-18

No results posted yet for this study

Summary

Drug drug interaction study between PF-05221304 and PF-06865571

Conditions

  • Healthy

Interventions

DRUG

PF-06865571 administered Day 7-14

PF-06865571 administered Q12hr on Days 7-14

DRUG

PF-06865571 administered Day 1-14

PF-06865571 administered Q12hr on Day 7-14

DRUG

PF-05221304 administered Day 1-14

PF-05221304 administered Q12hr on Days 1-14

DRUG

PF-05221304 administered Day 7-14

PF-05221304 administered Q12hr Days 7-14

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-19
Primary Completion
2018-07-16
Completion
2018-08-29
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03534648 on ClinicalTrials.gov